Pharmaceuticals and Healthcare

GSK plans to spin off Consumer Healthcare unit

GlaxoSmithKline (GSK) has plans to spin off its Consumer Healthcare unit by demerging a minimum of 80% of the company’s 68% stake to its shareholders.

Xeris Pharmaceuticals to acquire Strongbridge Biopharma for $267m

US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m.

USFDA approves Janssen’s PONVORY for treatment of multiple sclerosis

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

USFDA extends review period for AbbVie’s sNDA of upadacitinib

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.

USFDA grants FTD to efanesoctocog alfa for hemophilia A treatment

The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.

Sandoz to acquire GlaxoSmithKline’s cephalosporin antibiotics business

Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.

AstraZeneca signs LOI with IDT Biologika to boost Europe’s Covid-19 vaccine-making capability

Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.

USFDA approves Libtayo for skin cancer treatment

The US Food and Drug Administration (FDA) has approved Libtayo to be used for the treatment of patients having two of the most common skin cancers in the US.

Mylan, Pfizer announce Viatris as new company name

Mylan and Pfizer announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris.